MedTrace Logo

Study of Rifaximin in Minimal Hepatic Encephalopathy

NCT01069133 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-12-11

No results posted yet for this study

Summary

Rifaximin therapy will improve brain functioning on MRI scanning and change the microbiome and metabolome.

Conditions

  • Minimal Hepatic Encephalopathy

Interventions

DRUG

Rifaximin

550mg BID open-label

DRUG

rifaximin

550mg PO BID

Sponsors & Collaborators

  • Bausch Health Americas, Inc.

    collaborator INDUSTRY

  • Hunter Holmes Mcguire Veteran Affairs Medical Center

    lead FED

Principal Investigators

  • Jasmohan S Bajaj, MD, MSc · McGuire VA Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2012-05-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01069133 on ClinicalTrials.gov